Shandong Boan Biotechnology Co., Ltd. (HKG:6955)

Hong Kong · Delayed Price · Currency is HKD

2.435

-0.125 (-4.88%)

Sep 18, 2026, 4:08 PM HKT

Market Cap	1.52B -83.0%
Revenue (ttm)	720.87M -17.5%
Net Income	-111.27M
EPS	-0.19
Shares Out	622.33M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,731,200
Open	2.590
Previous Close	2.560
Day's Range	2.400 - 2.590
52-Week Range	2.410 - 15.140
Beta	0.03
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About HKG:6955

Shandong Boan Biotechnology Co., Ltd., a biopharmaceutical company, develops, manufactures, and markets biologics in Mainland China. The company offers Boyounuo (BA1101), an anti-VEGF humanized monoclonal antibody injection for mCRC, advanced metastatic or recurrent non-small cell lung cancer, recurrent glioblastoma, epithelial ovarian, fallopian tube, primary peritoneal cancer, cervical cancer, and hepatocellular carcinoma indications; Boyoubei (BA6101), a human immunoglobulin G2 monoclonal antibody of the RANK ligand for the treatment of post... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2013

Employees 690

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 6955

Full Company Profile

Financial Performance

In 2025, HKG:6955's revenue was 784.82 million, an increase of 8.06% compared to the previous year's 726.32 million. Earnings were 7.14 million, a decrease of -90.24%.

Financial numbers in CNY Financial Statements